Clinical study on the benefits of combined application of lumbrokinase and Tongxinluo in elderlypatients with severe cerebral vascular stenosis
重度脑血管狭窄老年脑梗死患者联合应用蚓激酶及通心络的获益临床研究

摘要

目的 分析重度脑血管狭窄老年脑梗死患者联合应用蚓激酶及通心络的获益临床效果。方法 对照组使用阿司匹林联合瑞舒伐他汀进行治疗，观察组在此基础之上增加蚓激酶联合通心络进行治疗。对比两组患者的血管狭窄程度改善情况、神经系统评分情况以及相关指标变化情况。结果 观察组患者血管狭窄程度改善情况好于对照组，两组之间具有显著差异（P＜0.05），观察组患者神经系统评分情况好于对照组，两组之间具有显著差异（P＜0.05）。观察组患者血浆D-二聚体，超敏C-反应蛋白相关指标好于对照组，具有显著差异（P＜0.05）。观察组治疗有效率高于对照组，不良反应发生率低于对照组，具有显著差异（P＜0.05）。结论 蚓激酶联合通心络治疗方法对于重度脑血管狭窄老年脑梗死患者具有良好的治疗效果，经治疗，患者的急性脑血管病变发生概率降低，血管狭窄改善程度良好，且患者的溶栓效果良好，自理能力显著提升，生存质量改善。经治疗，患者的斑块形成以及血管狭窄的炎性介质分泌情况改善，可推广。

Abstract

Objective To analyze the clinical effect of combined use of lumbrokinase and Tongxinluo in elderly patients with cerebral infarction with severe cerebral vascular stenosis.
Methods The control group was treated with aspirin combined with rosuvastatin, and the observation group was treated with lumbrokinase combined with Tongxinluo on this basis. The improvement of the degree of vascular stenosis, the score of the nervous system and the changes of related indicators were compared between the two groups.
Results The improvement of the degree of vascular stenosis in the observation group was better than that in the control group, and there was a significant difference between the two groups (P<0.05). 0.05). The plasma D-dimer and high-sensitivity C-reactive protein-related indexes of the observation group were better than those of the control group, with significant difference (P<0.05). The effective rate of treatment in the observation group was higher than that in the control group, and the incidence of adverse reactions was lower than that in the control group, with significant differences (P<0.05).
Conclusion   Lumbrokinase combined with Tongxinluo therapy has a good therapeutic effect on elderly patients with cerebral infarction with severe cerebral vascular stenosis. After treatment, the incidence of acute cerebrovascular disease in patients is reduced, the degree of improvement in vascular stenosis is good, and the thrombolytic effect of patients is improved. Good, the self-care ability has been significantly improved, and the quality of life has improved. After treatment, the patient's plaque formation and the secretion of inflammatory mediators of vascular stenosis improved, which can be promoted.